On this page
What is Graves’ Ophthalmopathy (Thyroid Eye Disease)?
Graves’ ophthalmopathy (also known as thyroid eye disease (TED), thyroid-associated orbitopathy (TAO), or Basedow’s exophthalmos) is a clinical condition involving the eyes and the orbital tissues that occurs as a characteristic manifestation of Graves’ disease, an autoimmune form of hyperthyroidism.
In Graves’ ophthalmopathy, the autoimmune process that disrupts thyroid function also targets the tissues of the eye socket (orbit), causing inflammation, swelling, and scarring of the muscles, fat, and connective tissue surrounding the eyeball.
Clinical Manifestations
The spectrum of ocular involvement can range from mild and cosmetically noticeable to severe and vision-threatening. Recognized manifestations include:
- Exophthalmos (proptosis): Forward protrusion of one or both eyeballs from the orbit, giving the eyes a characteristic “staring” or “bulging” appearance. It may affect both eyes symmetrically or asymmetrically.
- Eye pain: Often intense and worsened by eye movement
- Eyelid edema: Swelling and puffiness of the upper and/or lower eyelids
- Ophthalmoplegia: Impaired coordination of the extraocular muscles, leading to restricted or painful eye movements
- Burning and eye redness: Particularly pronounced upon waking
- Dry eye syndrome: Due to incomplete eyelid closure (lagophthalmos)
- Foreign body sensation: A gritty or scratchy feeling in the eye
- Blurred or reduced vision
- Photophobia: Abnormal sensitivity to light
- Chemosis: Swelling and redness of the conjunctiva (the transparent membrane covering the white of the eye)
- Diplopia: Double vision, caused by muscle imbalance
- Excessive tearing (epiphora)
- Optic neuropathy: Compression of the optic nerve by enlarged orbital muscles or fat, which is the most dangerous complication and may cause permanent vision loss.
- Corneal ulceration: Damage to the outer transparent layer of the eye, resulting from incomplete closure of the eyelids and chronic dryness
Graves’ ophthalmopathy is intrinsically linked to the underlying Graves’ disease, and effective management requires treatment of the thyroid condition first. Once thyroid function is stabilized, targeted ophthalmologic therapy can be planned based on disease severity. This may include pharmacological or surgical options.
Overview of Graves’ Disease
Graves’ disease is a chronic autoimmune disorder that primarily targets the thyroid gland. It is the most common cause of hyperthyroidism in the developed world, particularly affecting women of reproductive age.
The disease is characterized by the production of abnormal antibodies. Most importantly, these include TSH receptor antibodies (TRAb), which mimic the action of thyroid-stimulating hormone (TSH). As a result, the thyroid gland produces excessive amounts of thyroid hormones and enlarges, forming a diffuse goiter.
Graves’ disease is classically described by a triad of findings:
-
Thyroid dysfunction: Almost always, hyperthyroidism involves elevated circulating thyroid hormones (T3 and T4) and suppressed TSH. This condition is typically accompanied by an enlarged, diffusely hyperactive thyroid gland.
-
Graves’ ophthalmopathy: The characteristic ocular involvement described above, driven by autoantibodies that also target antigens shared between the thyroid and the orbital fibroblasts (the cells that produce connective tissue within the orbit). This cross-reactivity leads to orbital inflammation, enlargement of the extraocular muscles, and expansion of orbital fat volume.
-
Infiltrative dermopathy (pretibial myxedema): A less common manifestation that presents as firm, non-pitting swelling of the skin on the lower legs. This usually affects the shin area and may include itching, skin redness, tingling, or a sensation of heaviness or pain in the legs.
The autoimmune trigger is thought to involve a combination of genetic susceptibility and environmental factors. The disease is particularly prevalent in regions with endemic iodine deficiency, as iodine is an essential substrate for thyroid hormone synthesis.
Risk Factors
The following factors are associated with an increased likelihood of developing Graves’ disease and its ophthalmopathy:
- Genetic predisposition: A family history of Graves’ disease or other autoimmune thyroid conditions (such as Hashimoto’s thyroiditis) significantly increases risk. Certain HLA haplotypes are associated with susceptibility.
- Female sex: Women are approximately 5–10 times more likely to develop Graves’ disease than men, although men who develop it tend to have more severe ophthalmopathy.
- Age: Although it can occur at any age, peak incidence is between 30 and 50 years.
- Pre-existing thyroid disorders: Any thyroid dysfunction, whether prior hypothyroidism, nodular disease, or thyroiditis, increases vulnerability.
- Cigarette smoking: One of the strongest and most consistently demonstrated modifiable risk factors specifically for Graves’ ophthalmopathy. Smokers have a significantly higher risk of developing the eye disease, and it tends to be more severe in smokers. Smoking cessation is therefore a critical therapeutic recommendation.
- Radioiodine therapy: Treatment of hyperthyroidism with radioactive iodine (I-131) can transiently worsen pre-existing ophthalmopathy in some patients, particularly smokers.
- Psychological stress and other immune-modulating conditions: May act as precipitating factors in genetically predisposed individuals.
How Does Graves’ Ophthalmopathy Present?
It is important to understand that any thyroid dysfunction, whether hyperthyroidism or hypothyroidism, can be associated with the appearance or worsening of Graves’ ophthalmopathy. The eye disease shares the same fundamental autoimmune mechanism as the thyroid dysfunction but can follow an independent clinical course. It may precede, coincide with, or follow the onset of thyroid disease. In some patients, it may even occur when thyroid function appears normal, a condition known as euthyroid Graves’ ophthalmopathy.
The condition develops gradually, and its severity varies considerably between patients. Ophthalmopathy tends to be more severe in men and in smokers.
The Active vs. Inactive Phase
Clinicians classify Graves’ ophthalmopathy into two phases:
- Active (inflammatory) phase: Characterized by progressive worsening of symptoms, orbital inflammation, pain, redness, and edema. This phase can last from 6 months to 2 years. Treatment is most effective during this phase.
- Inactive (fibrotic) phase: The inflammatory activity subsides, and the condition stabilizes. However, some forms of structural damage, such as proptosis, diplopia, and eyelid changes, may persist and require surgical correction.
Key Clinical Signs
The most prominent and diagnostically significant feature remains exophthalmos, also known as proptosis. This condition involves the forward displacement of the eyeballs. It occurs when the orbital contents, including enlarged muscles and increased fat volume, expand within the rigid bony orbit. Because the orbit cannot expand to accommodate the increased volume, intraorbital pressure rises and pushes the eye forward.
This forward displacement may impair the ability to fully close the eyelids (lagophthalmos), leaving the cornea exposed and vulnerable to drying and ulceration.
Additional notable clinical manifestations include:
- Eye pain: Intense, frequent, often worsened by eye movement in all directions.
- Eyelid edema and retraction: The upper eyelid appears pulled upward, exposing the sclera (the white of the eye) above the iris. This contributes to the characteristic wide-eyed stare.
- Ophthalmoplegia: Loss of coordinated movement of the extraocular muscles. This condition often causes restricted upward gaze and may lead to double vision, also known as diplopia.
- Burning and redness: Particularly severe upon waking, due to overnight eyelid exposure.
- Dry eye: From reduced blink frequency and incomplete lid closure.
- Foreign body sensation: Constant and distressing.
- Blurred vision and visual field defects: Warning signs of optic nerve involvement.
- Photophobia: Heightened sensitivity to light.
- Chemosis: Visible swelling and redness of the conjunctiva.
- Diplopia: Double vision, often worse on upward or lateral gaze.
- Epiphora: Overflow of tears due to drainage impairment from swollen tissues.
- Corneal ulceration: A sight-threatening complication of severe exposure keratopathy.
Red flag symptoms requiring urgent specialist assessment include sudden reduction in visual acuity or color vision, severe optic disc edema, or rapidly worsening proptosis. These symptoms may indicate dysthyroid optic neuropathy, which can cause irreversible blindness if untreated.
Diagnosis
The diagnosis of Graves’ ophthalmopathy relies on clinical and instrumental assessments. It requires collaboration between an endocrinologist and an ophthalmologist, and in complex cases, an orbital surgeon or neuro-ophthalmologist may also be involved.
Specialist Consultations
Endocrinological evaluation: The endocrinologist confirms the diagnosis of Graves’ disease through:
- Measurement of thyroid function tests: TSH (suppressed), free T4 and free T3 (elevated).
- Detection of TRAb (TSH receptor antibodies), the pathognomonic antibody of Graves’ disease, is present in over 95% of affected patients.
- Thyroid ultrasound: typically shows a diffusely enlarged, hypervascular gland
Ophthalmological evaluation: The ophthalmologist assesses the full extent of ocular involvement through:
- Visual acuity and color vision testing
- Pupillary reflexes and fundoscopy (examination of the optic disc)
- Exophthalmometry (Hertel exophthalmometer): Quantifies the degree of proptosis in millimeters
- Slit-lamp examination: evaluates the cornea, conjunctiva, and anterior segment
- Assessment of eyelid position and closure
- Ocular motility testing: identifies restriction and diplopia
- Intraocular pressure measurement
The Clinical Activity Score (CAS) is a standardized tool used to quantify the degree of inflammatory activity and guide therapeutic decisions. It assigns points to seven clinical signs of inflammation (pain, redness, chemosis, lid edema, etc.), with a score ≥ 3/7 indicating active disease.
Distinctive clinical signs that may be evaluated during examination include:
- Dalrymple’s sign: Upper eyelid retraction, with scleral show above the limbus and proptotic appearance
- von Graefe’s sign: Failure of the upper eyelid to follow downward gaze smoothly (lid lag)
- Joffroy’s sign: Absence of forehead wrinkling on upward gaze
- Moebius’ sign: Impaired convergence for near vision
Imaging Studies
When clinical assessment suggests significant orbital involvement, or when optic neuropathy is suspected, imaging is indicated:
- CT scan (Computed Tomography): The first-line imaging modality for the orbit. It provides detailed visualization of the extraocular muscles (which appear fusiform-enlarged in Graves’ ophthalmopathy), the optic nerve at the orbital apex, and the bony orbital walls. It is indispensable for surgical planning.
- MRI (Magnetic Resonance Imaging): Superior to CT for evaluating soft tissue detail, especially the optic nerve at the orbital apex and the inflammatory activity within the orbital fat and muscles. MRI signal characteristics can help differentiate the active (edematous) phase from the inactive (fibrotic) phase.
- Visual Evoked Potentials (VEPs): A neurophysiological test conducted by a specialist to objectively evaluate the functional integrity of the optic nerve. This test is often performed before and after treatment to monitor response.
Treatment
Treatment of Graves’ ophthalmopathy is guided by two key parameters: the severity of the eye disease and its activity (inflammatory vs. fibrotic phase). Crucially, treatment of the underlying thyroid dysfunction is a prerequisite for any ophthalmologic intervention.
Step 1: Treat the Underlying Thyroid Disease
Normalizing thyroid function is the foundational step. Options for treating hyperthyroidism in Graves’ disease include:
- Antithyroid drugs (e.g., methimazole, carbimazole, propylthiouracil).
- Radioiodine therapy (I-131): Effective, but it may temporarily worsen ophthalmopathy. In patients with active eye disease, corticosteroid prophylaxis is often prescribed at the same time.
- Thyroidectomy (surgical removal of the thyroid): May be preferred in patients with severe or rapidly progressive ophthalmopathy to minimize immunological fluctuations.
Step 2: Supportive Measures (Mild Disease)
For patients with mild or inactive disease, supportive symptomatic measures are often sufficient:
- Artificial tears and lubricating eye drops: Relieve dry eye, foreign body sensation, and corneal irritation. Preservative-free formulations are preferred for frequent use.
- Nighttime lubricating ointments: Protect the cornea during sleep when incomplete lid closure causes nocturnal exposure
- Beta-blocker eye drops: Indicated when elevated intraocular pressure is present
- Prism glasses: Can alleviate mild, stable diplopia without surgery
- Selenium supplementation: A randomized controlled trial (EUGOGO 2011) demonstrated that oral selenium, given at 200 mcg/day for 6 months, significantly improved mild active Graves’ ophthalmopathy and quality of life. As a result, it is now incorporated into European guidelines for mild active disease.
- Smoking cessation: Absolutely essential, as smoking worsens ophthalmopathy progression and reduces the response to treatment.
Step 3: Immunosuppressive Therapy (Moderate-to-Severe Active Disease)
For moderate-to-severe active Graves’ ophthalmopathy (CAS ≥ 3), anti-inflammatory and immunosuppressive therapy is indicated:
- Intravenous glucocorticoids (corticosteroids): High-dose intravenous methylprednisolone (pulse therapy) is the first-line treatment for active, moderate-to-severe disease. It reduces orbital inflammation, may stabilize or reduce proptosis, and decreases the risk of optic neuropathy. Oral corticosteroids are less effective and associated with more side effects. Close monitoring for corticosteroid-related adverse effects (hyperglycemia, hypertension, hepatotoxicity) is mandatory.
- Orbital radiotherapy: External beam radiation therapy to the orbit can reduce inflammation and complement corticosteroid therapy in patients who do not respond adequately to steroids alone. It is particularly effective in reducing diplopia and soft tissue changes.
- Teprotumumab: A monoclonal antibody targeting the IGF-1 receptor, recently approved by the FDA for Graves’ ophthalmopathy. Clinical trials have demonstrated remarkable reductions in proptosis (averaging 2–3 mm) and clinical activity scores, representing a major therapeutic advance.
- Rituximab (anti-CD20 monoclonal antibody): Targets B lymphocytes involved in antibody production; used in selected refractory cases.
Step 4: Surgical Rehabilitation (Inactive Disease)
Surgery is reserved for stable, inactive disease (after the inflammatory phase has subsided) to correct residual structural abnormalities. The sequence of surgical steps, when multiple are needed, follows a specific order:
1. Orbital Decompression
The primary surgical option for significant proptosis or vision-threatening optic neuropathy. It may be performed urgently (for optic neuropathy) or electively (for cosmetic or exposure concerns). Two main techniques are used:
- Bony decompression: Performed under general anesthesia, involves surgical removal or displacement of one or more orbital walls (most commonly the medial and/or inferior wall) to enlarge the bony cavity, allowing the orbital contents to expand backward and reducing intraorbital pressure
- Fat decompression (lipectomy): Involves removal of excess orbital fat under general anesthesia, also creating more space and reducing forward pressure on the eyeball
- Combined technique: Both bony and fat decompression are performed together in cases of particularly severe proptosis
2. Strabismus Surgery (Squint Surgery)
Performed after orbital decompression has stabilized, to correct diplopia caused by muscle imbalance. Involves adjusting the tension of one or more extraocular muscles.
3. Eyelid Surgery
The last step, performed after orbital and muscle surgery, corrects eyelid retraction and restores both normal eyelid position and cosmetic appearance.
Sources and Bibliography
- Rugarli C. Medicina interna sistematica. Edra Masson, 7th edition, 2015.
- Polimeni A, Filipo R, Iannetti G. Manuale di patologia degli organi di senso. Edra, 2014.
- Eckstein A, Dekowski D, Führer-Sakel D, et al. “Graves’ ophthalmopathy”. Ophthalmologe. 2016 Apr;113(4):349–364.
- Eckstein A, Berchner-Pfannschmidt U, Führer D, Esser J. “Update on endocrine orbitopathy”. Ophthalmologe. 2013 Nov;110(11):1079–1096.
- Bartalena L, et al. “The 2021 European Group on Graves’ Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy”. European Journal of Endocrinology, 2021.
- Marcocci C, et al. “Selenium and the course of mild Graves’ orbitopathy”. New England Journal of Medicine, 2011.
- Douglas RS, et al. “Teprotumumab for the treatment of active thyroid eye disease”. New England Journal of Medicine, 2020.
